RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sartorius Stedim Biotech Stock

Sartorius Stedim Biotech EBIT 2024

Sartorius Stedim Biotech EBIT

521.58 M EUR

Ticker

DIM.PA

ISIN

FR0013154002

WKN

A2AJKS

In 2024, Sartorius Stedim Biotech's EBIT was 521.58 M EUR, a 10.9% increase from the 470.3 M EUR EBIT recorded in the previous year.

The Sartorius Stedim Biotech EBIT history

YEAREBIT (undefined EUR)
2030e1.9
2029e1.75
2028e1.23
2027e1.09
2026e0.78
2025e0.63
2024e0.52
20230.47
20221.08
20210.88
20200.5
20190.35
20180.29
20170.25
20160.24
20150.2
20140.12
20130.11
20120.09
20110.08
20100.06
20090.05
20080.04
20070.02
20060.01
20050.01
20040.01

Sartorius Stedim Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sartorius Stedim Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sartorius Stedim Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sartorius Stedim Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sartorius Stedim Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sartorius Stedim Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sartorius Stedim Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sartorius Stedim Biotech’s growth potential.

Sartorius Stedim Biotech Revenue, EBIT and net profit per share

DateSartorius Stedim Biotech RevenueSartorius Stedim Biotech EBITSartorius Stedim Biotech Net Income
2030e5.72 B undefined1.9 B undefined1.5 B undefined
2029e5.24 B undefined1.75 B undefined1.21 B undefined
2028e4.74 B undefined1.23 B undefined1.07 B undefined
2027e4.28 B undefined1.09 B undefined926.09 M undefined
2026e3.46 B undefined781.53 M undefined559.08 M undefined
2025e3.09 B undefined633.48 M undefined445.98 M undefined
2024e2.83 B undefined521.58 M undefined353.35 M undefined
20232.78 B undefined470.3 M undefined309.7 M undefined
20223.49 B undefined1.08 B undefined876.1 M undefined
20212.89 B undefined882.98 M undefined414.41 M undefined
20201.91 B undefined503.45 M undefined335.93 M undefined
20191.44 B undefined348.65 M undefined234.5 M undefined
20181.21 B undefined287.52 M undefined208.05 M undefined
20171.08 B undefined251.38 M undefined161.09 M undefined
20161.05 B undefined241.74 M undefined153.68 M undefined
2015884.33 M undefined197.64 M undefined118 M undefined
2014683.52 M undefined122.51 M undefined72.44 M undefined
2013588.38 M undefined105.44 M undefined66.28 M undefined
2012543.96 M undefined92.29 M undefined56.76 M undefined
2011477.3 M undefined80.19 M undefined43.05 M undefined
2010432.95 M undefined62.9 M undefined38.51 M undefined
2009401.23 M undefined53.25 M undefined29.09 M undefined
2008368 M undefined35.61 M undefined13.09 M undefined
2007268.84 M undefined22.35 M undefined4.74 M undefined
200691.37 M undefined11.46 M undefined6.69 M undefined
200585.74 M undefined9.19 M undefined6.9 M undefined
200464.06 M undefined7.01 M undefined5.58 M undefined

Sartorius Stedim Biotech stock margins

The Sartorius Stedim Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sartorius Stedim Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sartorius Stedim Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sartorius Stedim Biotech's sales revenue. A higher gross margin percentage indicates that the Sartorius Stedim Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sartorius Stedim Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sartorius Stedim Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sartorius Stedim Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sartorius Stedim Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sartorius Stedim Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sartorius Stedim Biotech Margin History

Sartorius Stedim Biotech Gross marginSartorius Stedim Biotech Profit marginSartorius Stedim Biotech EBIT marginSartorius Stedim Biotech Profit margin
2030e44.44 %33.24 %26.19 %
2029e44.44 %33.33 %23.03 %
2028e44.44 %26 %22.47 %
2027e44.44 %25.49 %21.64 %
2026e44.44 %22.61 %16.18 %
2025e44.44 %20.51 %14.44 %
2024e44.44 %18.46 %12.51 %
202344.44 %16.94 %11.16 %
202252.52 %31 %25.08 %
202153.79 %30.58 %14.35 %
202052.53 %26.36 %17.59 %
201951.94 %24.2 %16.28 %
201851.94 %23.72 %17.16 %
201751.32 %23.25 %14.9 %
201650.1 %22.99 %14.61 %
201551.09 %22.35 %13.34 %
201449.33 %17.92 %10.6 %
201349.82 %17.92 %11.26 %
201249.98 %16.97 %10.43 %
201149.95 %16.8 %9.02 %
201049.81 %14.53 %8.9 %
200947.44 %13.27 %7.25 %
200847.77 %9.68 %3.56 %
200744.42 %8.31 %1.76 %
200644.15 %12.55 %7.32 %
200542.02 %10.72 %8.05 %
200441.12 %10.94 %8.7 %

Sartorius Stedim Biotech Aktienanalyse

What does Sartorius Stedim Biotech do?

Sartorius Stedim Biotech SA is a company specializing in the development, manufacturing, and marketing of products and services for the biopharmaceutical industry. It was formed in 2007 through the merger of two companies, Sartorius and Stedim Biotech, and is headquartered in Aubagne, France. The company has a history dating back to 1870 when Florenz Sartorius, a mechanic, founded a precision scale factory in Göttingen, Germany. Over the years, Sartorius became a leading provider of laboratory scales and equipment worldwide. In 1951, the company was renamed Sartorius AG and expanded into filtration technology. Stedim Biotech, on the other hand, was founded in 1957 as a manufacturer of plastic products and is based in Aubagne, France. It has since become a leading provider of products and services for the biopharmaceutical industry. Today, Sartorius Stedim Biotech SA operates in four business segments: bioprocess systems, laboratory equipment, services, and specialized products. Its bioprocess systems segment includes products and solutions for biopharmaceutical production such as fermenters, bioreactors, cryogenic storage tanks, and filtration systems. The laboratory equipment segment offers a wide range of lab products including scales, pipettes, and analysis devices. The services segment includes consulting, training, and technical services for the biopharmaceutical industry. Lastly, the specialized products segment provides a broad range of products for specific applications, such as disposable syringes for medication administration. Sartorius Stedim Biotech SA has developed a wide range of products for the biopharmaceutical industry, including fermenters and bioreactors for the production of biological drugs, filtration systems for protein purification and cell culture media, disposable syringes for medication administration, and laboratory equipment for sample analysis. The company's business model is to offer a comprehensive range of products and services for the biopharmaceutical industry. It focuses on high-quality and innovative products and services, as well as providing consultation and support to its customers in solving challenges in biopharmaceutical production. Overall, Sartorius Stedim Biotech SA is a leading provider of products and services for the biopharmaceutical industry. Its broad product range and consultancy and support services make it an important partner for the biopharmaceutical industry in the production of biological drugs. Sartorius Stedim Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Sartorius Stedim Biotech's EBIT

Sartorius Stedim Biotech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Sartorius Stedim Biotech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Sartorius Stedim Biotech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Sartorius Stedim Biotech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Sartorius Stedim Biotech stock

How much did Sartorius Stedim Biotech achieve in EBIT for the current year?

In the current year, Sartorius Stedim Biotech has achieved an EBIT of 521.58 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Sartorius Stedim Biotech.

How has the EBIT of Sartorius Stedim Biotech developed in recent years?

The EBIT of Sartorius Stedim Biotech has increased by 10.904% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Sartorius Stedim Biotech?

The EBIT of Sartorius Stedim Biotech is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Sartorius Stedim Biotech pay?

Over the past 12 months, Sartorius Stedim Biotech paid a dividend of 2.88 EUR . This corresponds to a dividend yield of about 1.68 %. For the coming 12 months, Sartorius Stedim Biotech is expected to pay a dividend of 3.69 EUR.

What is the dividend yield of Sartorius Stedim Biotech?

The current dividend yield of Sartorius Stedim Biotech is 1.68 %.

When does Sartorius Stedim Biotech pay dividends?

Sartorius Stedim Biotech pays a quarterly dividend. This is distributed in the months of April, April, April, May.

How secure is the dividend of Sartorius Stedim Biotech?

Sartorius Stedim Biotech paid dividends every year for the past 27 years.

What is the dividend of Sartorius Stedim Biotech?

For the upcoming 12 months, dividends amounting to 3.69 EUR are expected. This corresponds to a dividend yield of 2.15 %.

In which sector is Sartorius Stedim Biotech located?

Sartorius Stedim Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sartorius Stedim Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sartorius Stedim Biotech from 4/4/2024 amounting to 0.69 EUR, you needed to have the stock in your portfolio before the ex-date on 4/2/2024.

When did Sartorius Stedim Biotech pay the last dividend?

The last dividend was paid out on 4/4/2024.

What was the dividend of Sartorius Stedim Biotech in the year 2023?

In the year 2023, Sartorius Stedim Biotech distributed 2.52 EUR as dividends.

In which currency does Sartorius Stedim Biotech pay out the dividend?

The dividends of Sartorius Stedim Biotech are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Sartorius Stedim Biotech stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Sartorius Stedim Biotech

Our stock analysis for Sartorius Stedim Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sartorius Stedim Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.